SPY312.23+1.71 0.55%
DIA258.42+1.11 0.43%
IXIC10,207.63+53.00 0.52%

Intersect ENT Sees Prelim. FY19 Sales $109M vs $108.71M Est., Sees FY20 Sales $115M-$119M vs $119.69M Est.

MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company transforming care for patients with ear, nose and throat conditions, today reported preliminary unaudited revenue for the full year ended

Benzinga · -

MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company transforming care for patients with ear, nose and throat conditions, today reported preliminary unaudited revenue for the full year ended December 31, 2019.

Full Year 2019 Preliminary Revenue

Preliminary unaudited revenue for the full year 2019 is expected to be approximately $109 million, in line with guidance given in midyear 2019. The expected 2019 revenue includes preliminary SINUVA® revenue of approximately $4.5 million for the full year 2019 with the remaining revenue comprised of sales of the PROPEL® family of products.

The full year 2019 revenue included in this release is preliminary and prior to the completion of review and audit procedures by Intersect ENT's external auditors and is therefore subject to adjustment.

Intersect ENT expects to provide its full year 2019 financial results and further 2020 guidance during its fourth quarter 2019 earnings call in late February 2020.

2020 Revenue Outlook

The company forecasts full year 2020 revenue in the range of $115 to $119 million. On a quarterly basis, we expect revenue growth to build throughout the year.